176
Participants
Start Date
August 27, 2020
Primary Completion Date
June 1, 2031
Study Completion Date
June 1, 2032
Early treatment of relapse with carfilzomib, dexamethasone, daratumumab
Second line treatment will start at MRD reapperance
Standard treatment of relapse with carfilzomib, dexamethasone, daratumumab
Second line treatment will start at progressive disease
RECRUITING
Ålesund Hospital, Ålesund
RECRUITING
Haukeland University Hospital, Bergen
RECRUITING
Nordland Hospital Bodø, Bodø
RECRUITING
Sykehuset Ostfold, Fredrikstad
RECRUITING
Førde Central Hospital, Førde
RECRUITING
Sørlandet Hospital Kristiansand, Kristiansand
RECRUITING
Levanger Hospital, Levanger
RECRUITING
Akershus University Hospital, Lørenskog
RECRUITING
Oslo University Hospital, Oslo
RECRUITING
Helse Stavanger HF, Stavanger
RECRUITING
University Hospital North Norway, Tromsø
RECRUITING
St. Olavs Hospital, Trondheim
RECRUITING
The Hospital of Vestfold, Tønsberg
St. Olavs Hospital
OTHER
Haukeland University Hospital
OTHER
University Hospital of North Norway
OTHER
University Hospital, Akershus
OTHER
Helse Stavanger HF
OTHER_GOV
Førde Central Hospital
OTHER
Sorlandet Hospital HF
OTHER_GOV
Nordlandssykehuset HF
OTHER
The Hospital of Vestfold
OTHER
Helse Nord-Trøndelag HF
OTHER
Alesund Hospital
OTHER
Sykehuset Ostfold
OTHER
Oslo University Hospital
OTHER